FGA
TCRT icon

Fortis Group Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Fortis Group Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,400
Closed -$9.79K – 518
2024
Q2 		$9.79K Hold
1,400
– – ﹤0.01% 299
2024
Q1 		$25.3K Buy
+1,400
New +$28K ﹤0.01% 252

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWM
Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

Fortis Group Advisors's TCRT Position: Q3 2024 in Review

Fortis Group Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2024, closing a stake of 1,400 shares — an estimated $9.79K sold.

Fortis Group Advisors first reported a position in TCRT in Q1 2024 and held it in 2 quarters. The position peaked at $25.3K in Q1 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q3 2024.

  • Fortis Group Advisors reported no remaining Alaunos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Fortis Group Advisors sold 1,400 Alaunos Therapeutics shares in Q3 2024, an estimated $9.79K.
  • Fortis Group Advisors first reported a position in Alaunos Therapeutics in Q1 2024 and held it in 2 quarters.
  • Fortis Group Advisors's Alaunos Therapeutics position peaked at $25.3K in Q1 2024.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2024.

Based on Fortis Group Advisors's 13F filing for Q3 2024, filed 21 Oct 2024.